Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;23(1):38-54.
doi: 10.1038/s41577-022-00746-9. Epub 2022 Jul 5.

IL-17 and IL-17-producing cells in protection versus pathology

Kingston H G Mills  1
Affiliations
Review

IL-17 and IL-17-producing cells in protection versus pathology

Kingston H G Mills. Nat Rev Immunol. 2023 Jan.

Abstract

IL-17 cytokine family members have diverse biological functions, promoting protective immunity against many pathogens but also driving inflammatory pathology during infection and autoimmunity. IL-17A and IL-17F are produced by CD4+ and CD8+ T cells, γδ T cells, and various innate immune cell populations in response to IL-1β and IL-23, and they mediate protective immunity against fungi and bacteria by promoting neutrophil recruitment, antimicrobial peptide production and enhanced barrier function. IL-17-driven inflammation is normally controlled by regulatory T cells and the anti-inflammatory cytokines IL-10, TGFβ and IL-35. However, if dysregulated, IL-17 responses can promote immunopathology in the context of infection or autoimmunity. Moreover, IL-17 has been implicated in the pathogenesis of many other disorders with an inflammatory basis, including cardiovascular and neurological diseases. Consequently, the IL-17 pathway is now a key drug target in many autoimmune and chronic inflammatory disorders; therapeutic monoclonal antibodies targeting IL-17A, both IL-17A and IL-17F, the IL-17 receptor, or IL-23 are highly effective in some of these diseases. However, new approaches are needed to specifically regulate IL-17-mediated immunopathology in chronic inflammation and autoimmunity without compromising protective immunity to infection.

PubMed Disclaimer

Conflict of interest statement

K.H.G.M. is a co-founder and shareholder in a Biotech start-up company involved in the development of anti-inflammatory therapeutics.

Figures

Fig. 1
Fig. 1. Drug targets in the IL-23–IL-17 pathway.
Activation of dendritic cells (DCs) and macrophages through pathogen recognition receptors (PRRs) promotes production of IL-23 and IL-1β, which play a major role in the induction and/or expansion of populations of T helper 17 (TH17) cells, IL-17-secreting γδ T (γδT17) cells and other IL-17-secreting cells (not shown). By contrast IL-12 production by DCs and macrophages promotes development of TH1 cells. Monoclonal antibodies (mAbs) that neutralize IL-12p40 (ustekinumab) suppress TH1 cell as well as TH17 cell and γδT17 cell responses, whereas mAbs that neutralize IL-23 (guselkumab, tildrakizumab and risankizumab) specifically block IL-17-secreting cells. The RORγt transcriptional factor is the master regulator of IL-17 production in diverse cell types and a target for small molecule drugs (SMDs) in development. TH17 cells, γδT17 cells and other IL-17-secreting cells (not shown) co-produce IL-17A and IL-17F and, while most of the focus has been on mAbs specific for IL-17A (secukinumab and ixekizumab), antibodies that neutralize both IL-17A and IL-17F (bimekizumab) are also in clinical use. These, together with mAbs that bind to IL-17RA (brodalumab) and inhibit binding of IL-17A and IL-17F to IL-17RA–IL-17RC, appear to be marginally more effective than anti-IL-17A mAbs. Finally, peptides, macrocycles and other SMDs that target IL-17R or ACT1 are also in development. GM-CSF, granulocyte–macrophage colony-stimulating factor; PAMP, pathogen-associated molecular pattern.
Fig. 2
Fig. 2. Role of IL-17 in protective immunity versus immunopathology.
During infection, pathogens release pathogen-associated molecular patterns (PAMPs) that bind to pattern recognition receptors (PRRs) and activate innate immune cells, including macrophages and dendritic cells (DCs), which present foreign peptide antigens to T cells and provide a source of T cell-polarizing cytokines. IL-1β and IL-23 activate T helper 17 (TH17) cells, IL-17-producing CD8+ T cells (IL-17+CD8+), type 3 innate lymphoid cells (ILC3s) and IL-17-secreting γδ T (γδT17) cells, which produce IL-17A and IL-17F as well as other pro-inflammatory cytokines (not shown) that promote the production of neutrophil-recruiting chemokines from epithelial cells (for example, in respiratory tract or intestine). IL-17, together with IFNγ, can also activate macrophages. Activated macrophages and neutrophils phagocytose and kill intracellular bacteria, fungi and protozoan parasites. IL-17A, IL-17F and IL-22 promote the production of antimicrobial peptides (AMPs) and enhance epithelial barrier function. In autoimmune diseases (or infection-indued immunopathology), the same responses, triggered by infection or damage during sterile inflammation (damage-associated molecular patterns; DAMPs), can promote auto-antigen-specific TH17 cells and γδT17 cells that produce IL-17A and IL-17F, which in combination with tumour necrosis factor (TNF), act on epithelial cells (for example, keratinocytes in psoriasis) to produce chemokines that recruit neutrophils and macrophages, promoting inflammation. IL-17 also activates the production of pro-inflammatory cytokines and matrix metalloproteinases (MMPs) that mediate the tissue damage and inflammation that lead to autoimmune diseases. CXCL, CXC-chemokine ligand.
Fig. 3
Fig. 3. Regulation of IL-17-producing cells that mediate pathology during infection or in autoimmune diseases.
IL-17A, IL-17F and tumour necrosis factor (TNF) produced by T helper 17 (TH17) cells, IL-17+CD8+ T cells or IL-17-secreting γδ T (γδT17) cells, and IFNγ produced by TH1 cells and natural killer (NK) cells recruit and/or activate neutrophils and macrophages that kill intracellular bacteria, fungi and small parasites. IL-17 and IL-22 also promote barrier function. These inflammatory responses can result in immunopathology and tissue damage unless they are tightly regulated. Regulation is mediated by thymically derived regulatory T (tTreg) cells, peripherally induced regulatory T (pTreg) cells, alternatively activated macrophages, TH2 cells and type 2 innate lymphoid cells (ILC2). These cells suppress effector T cells either through the production of immunosuppressive cytokines IL-10, TGFβ, IL-35, IL-4 and IL-13 or directly through the co-inhibitory molecules CTLA4 and PD1 expressed on tTreg cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rouvier E, Luciani MF, Mattéi MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 1993;150:5445–5456. - PubMed
    1. Yao Z, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995;3:811–821. doi: 10.1016/1074-7613(95)90070-5. - DOI - PubMed
    1. Taylor PR, et al. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat. Immunol. 2014;15:143–151. doi: 10.1038/ni.2797. - DOI - PMC - PubMed
    1. Tamassia N, et al. A reappraisal on the potential ability of human neutrophils to express and produce IL-17 family members in vitro: failure to reproducibly detect it. Front. Immunol. 2018;9:795. doi: 10.3389/fimmu.2018.00795. - DOI - PMC - PubMed
    1. Langrish CL, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005;201:233–240. doi: 10.1084/jem.20041257. - DOI - PMC - PubMed

Publication types